厄贝沙坦与厄贝沙坦/氢氯噻嗪复方制剂治疗轻中度原发性高血压的疗效对比观察(2)
总之，对于在社区就诊的轻中度原发性高血压患者，厄贝沙坦/氢氯噻嗪复方制剂治疗降压疗效满意，达标率高，且安全，不良反应少，是轻中度高血压患者的理想用药。
[参考文献]
[1] Hansson L，Zanchetti A，Carruthers SG，et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension： principal results of the Hypertension Optimal Treatment (HOT)randomised trial[J]. Lancet，1998，351(9118)：1755-1762.
[2] 孙宁玲，荆珊，陈捷. 厄贝沙坦/氢氯噻嗪复方片剂治疗中国高血压病患者的达标率分析[J]. 中华心血管病杂志，2005，33(7)：618-621.
[3] 陈少萍，郑兴，秦永文. 复方厄贝沙坦治疗原发性高血压的疗效观察[J]. 第二军医大学学报，2005，26(4)：164-166.
[4] 国高血压防治指南修订委员会. 中国高血压防治指南[J]. 中华高血压杂志，2011，19(8)：701-743.
[5] European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertension[J]. J Hypertens，2003，21(6)：1011-1053.
[6] Julius S，Kjeldsen SE，Weber M，et al. Outcomes in hypertensives patients a high cardiovascular risk treated with regimen based on valsartan OR amlodipine the value randomized trial[J]. Lancet，2004，363(9426)：2022-2031.
[7] Watchell K，Hornesstam B，Lehto M，et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation：The Losartan Intervention For End Point Reduction in Hypertension(LIFE) study[J]. JACC，2005，45(5)：705-711.
[8] Franse LV，Pahor M，Bari MD，et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertensionin the Elderly Program [J]. Hypertension，2002，35(5)：1025-1030.
(收稿日期：2012-05-10 本文编辑：赵丽萍), http://www.100md.com(赵凤梅 王成桓 肖燕兰)
[参考文献]
[1] Hansson L，Zanchetti A，Carruthers SG，et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension： principal results of the Hypertension Optimal Treatment (HOT)randomised trial[J]. Lancet，1998，351(9118)：1755-1762.
[2] 孙宁玲，荆珊，陈捷. 厄贝沙坦/氢氯噻嗪复方片剂治疗中国高血压病患者的达标率分析[J]. 中华心血管病杂志，2005，33(7)：618-621.
[3] 陈少萍，郑兴，秦永文. 复方厄贝沙坦治疗原发性高血压的疗效观察[J]. 第二军医大学学报，2005，26(4)：164-166.
[4] 国高血压防治指南修订委员会. 中国高血压防治指南[J]. 中华高血压杂志，2011，19(8)：701-743.
[5] European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertension[J]. J Hypertens，2003，21(6)：1011-1053.
[6] Julius S，Kjeldsen SE，Weber M，et al. Outcomes in hypertensives patients a high cardiovascular risk treated with regimen based on valsartan OR amlodipine the value randomized trial[J]. Lancet，2004，363(9426)：2022-2031.
[7] Watchell K，Hornesstam B，Lehto M，et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation：The Losartan Intervention For End Point Reduction in Hypertension(LIFE) study[J]. JACC，2005，45(5)：705-711.
[8] Franse LV，Pahor M，Bari MD，et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertensionin the Elderly Program [J]. Hypertension，2002，35(5)：1025-1030.
(收稿日期：2012-05-10 本文编辑：赵丽萍), http://www.100md.com(赵凤梅 王成桓 肖燕兰)